What if treating your allergies was as easy as….brushing your teeth? Well, with Intrommune Therapeutics, it now just might be! This New York City-based biopharmaceutical company is developing a toothpaste that uses oral mucosal immunotherapy (OMIT) to help people with peanut allergies overcome them. OMIT is based on allergy immunotherapy, which adheres to the idea that if patients receive tiny, carefully controlled amounts of the substance they are allergic to, their immune system learns that the substance is safe, and their allergic reactions become milder. Intrommune’s great-tasting, cavity-fighting toothpaste exposes patients to a low, safe dose of a peanut-derived protein in the toothpaste, with the goal of desensitizing the immune system’s reaction. They are developing this toothpaste in accordance to FDA guidelines, and there is no current FDA-approved treatment for any peanut for food allergy.
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
Edge
$25 /month billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data